Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma
Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.
EP: 1.The ‘Golden Age’ of Daratumumab: Highlights From an Expert Panel on Multiple Myeloma
EP: 2.Triplet and Quadruplet Induction Regimen Options for Patients With Transplant-Eligible NDMM
EP: 3.Data Updates From GRIFFIN and MASTER in Transplant-Eligible NDMM
EP: 4.Exploring the GMMG-CONCEPT Study in Patients With Transplant-Eligible NDMM
EP: 5.Assessing and Treating Patients with High-Risk NDMM
EP: 6.Treatment Approaches in Patients With Transplant-Ineligible NDMM
EP: 7.Subset Analysis of the MAIA Study in the Frail Multiple Myeloma Population
EP: 8.Available Treatment Options for Patients With R/R MM
EP: 9.Updated Results of the MonumenTAL-1 Study in R/R MM
EP: 10.Application of Bispecific Therapy in Clinical Practice
Now Viewing
EP: 11.Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma
EP: 12.Comparing Bispecifics and CAR T-Cell Therapy for Patients With MM
EP: 13.Unmet Needs in the Treatment of Multiple Myeloma
EP: 14.Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and Satellites
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
